- Report
- April 2024
- 175 Pages
Global
From €4778EUR$5,000USD£4,066GBP
- Report
- January 2024
- 175 Pages
Global
From €4778EUR$5,000USD£4,066GBP
- Report
- May 2024
- 137 Pages
Global
From €6211EUR$6,499USD£5,284GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
€1433EUR$1,500USD£1,220GBP
- Report
- November 2023
- 135 Pages
Global
From €3823EUR$4,000USD£3,252GBP
- Report
- April 2023
- 117 Pages
Global
From €4539EUR$4,750USD£3,862GBP
- Report
- October 2022
- 100 Pages
Global
From €2628EUR$2,750USD£2,236GBP
- Report
- January 2022
- 419 Pages
Global
From €9079EUR$9,500USD£7,725GBP
- Report
- May 2021
- 50 Pages
China
From €2485EUR$2,600USD£2,114GBP
- Report
- July 2018
- 33 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- July 2018
- 16 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- July 2018
- 17 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- July 2018
- 21 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Drug Pipelines
- February 2018
- 35 Pages
Global
From €9556EUR$10,000USD£8,131GBP
- Report
- June 2021
Global
From €3823EUR$4,000USD£3,252GBP
- Report
- January 2023
- 85 Pages
Europe
From €1433EUR$1,500USD£1,220GBP
- Report
- April 2023
- 156 Pages
Global
€4778EUR$5,000USD£4,066GBP
- Report
- April 2023
- 114 Pages
Global
€3345EUR$3,500USD£2,846GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €478EUR$500USD£407GBP
- Report
- January 2019
- 35 Pages
Global
From €956EUR$1,000USD£813GBP
Tiotropium is a long-acting anticholinergic drug used to treat chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. It is available in both an inhaler and a dry powder inhaler. Tiotropium is the only long-acting anticholinergic approved for the treatment of COPD. It is also used to treat asthma and other respiratory conditions.
Tiotropium is a popular drug in the respiratory drugs market, as it is effective in treating COPD and other respiratory conditions. It is also well-tolerated, with few side effects. It is available in both generic and brand-name forms, making it accessible to a wide range of patients.
Some companies in the Tiotropium market include Boehringer Ingelheim, GlaxoSmithKline, and Novartis. Show Less Read more